271 related articles for article (PubMed ID: 8428692)
1. Characterization of a human ovarian carcinoma cell line: UCI 101.
Fuchtner C; Emma DA; Manetta A; Gamboa G; Bernstein R; Liao SY
Gynecol Oncol; 1993 Feb; 48(2):203-9. PubMed ID: 8428692
[TBL] [Abstract][Full Text] [Related]
2. Characterization and development of UCI 107, a primary human ovarian carcinoma cell line.
Gamboa G; Carpenter PM; Podnos YD; Dorion G; Iravani L; Bolton D; Mascarello JT; Manetta A
Gynecol Oncol; 1995 Sep; 58(3):336-43. PubMed ID: 7672698
[TBL] [Abstract][Full Text] [Related]
3. Establishment and characterization of two human ovarian clear cell adenocarcinoma lines from metastatic lesions with different properties.
Gorai I; Nakazawa T; Miyagi E; Hirahara F; Nagashima Y; Minaguchi H
Gynecol Oncol; 1995 Apr; 57(1):33-46. PubMed ID: 7535723
[TBL] [Abstract][Full Text] [Related]
4. Novel phosphonium salts display in vitro and in vivo cytotoxic activity against human ovarian cancer cell lines.
Manetta A; Gamboa G; Nasseri A; Podnos YD; Emma D; Dorion G; Rawlings L; Carpenter PM; Bustamante A; Patel J; Rideout D
Gynecol Oncol; 1996 Feb; 60(2):203-12. PubMed ID: 8631539
[TBL] [Abstract][Full Text] [Related]
5. Failure to enhance the in vivo killing of human ovarian carcinoma by sequential treatment with dequalinium chloride and tumor necrosis factor.
Manetta A; Emma D; Gamboa G; Liao S; Berman M; DiSaia P
Gynecol Oncol; 1993 Jul; 50(1):38-44. PubMed ID: 8349163
[TBL] [Abstract][Full Text] [Related]
6. A newly established cel line derived from human ovarian adenocarcinoma.
Sekiguchi M; Sakakibara K; Suzuki T; Motoyama T; Fujii G
Jpn J Exp Med; 1980 Aug; 50(4):283-92. PubMed ID: 7441907
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a human carcinosarcoma cell line of the ovary established after in vivo change of histologic differentiation.
Möbus VJ; Gerharz CD; Weikel W; Merk O; Dreher L; Kreienberg R; Moll R
Gynecol Oncol; 2001 Dec; 83(3):523-32. PubMed ID: 11733966
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic values of prostaglandin D2 in nude mice bearing human ovarian carcinoma].
Kikuchi Y; Miyauchi M; Nagata I
Nihon Sanka Fujinka Gakkai Zasshi; 1990 Feb; 42(2):121-8. PubMed ID: 2313142
[TBL] [Abstract][Full Text] [Related]
9. Characterization of newly established cell line HUOA from a human ovarian serous cystadenocarcinoma.
Ishiwata I; Ishiwata C; Kobayashi N; Ishikawa H
Nihon Sanka Fujinka Gakkai Zasshi; 1987 May; 39(5):831-6. PubMed ID: 3598277
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of gamma-interferon in ascitic and solid tumor models of human ovarian cancer.
Malik ST; Knowles RG; East N; Lando D; Stamp G; Balkwill FR
Cancer Res; 1991 Dec; 51(24):6643-9. PubMed ID: 1742738
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice.
Bénard J; Da Silva J; De Blois MC; Boyer P; Duvillard P; Chiric E; Riou G
Cancer Res; 1985 Oct; 45(10):4970-9. PubMed ID: 3861241
[TBL] [Abstract][Full Text] [Related]
12. Establishment and characterization of a serous papillary adenocarcinoma cell line of the human ovary in a serum-free culture.
Emoto M; Oshima K; Ishiguro M; Iwasaki H; Kawarabayashi T; Kikuchi M
Pathol Res Pract; 1999; 195(4):237-42. PubMed ID: 10337661
[TBL] [Abstract][Full Text] [Related]
13. [Establishment and characterization of a human ovarian adenocarcinoma cell line OC-8611].
Huang JS
Zhonghua Zhong Liu Za Zhi; 1989 Nov; 11(6):416-8. PubMed ID: 2634538
[TBL] [Abstract][Full Text] [Related]
14. Characterization of CSOC 882, a novel immortalized ovarian cancer cell line expressing EGFR, HER2, and activated AKT.
Scoles DR; Pavelka J; Cass I; Tran H; Baldwin RL; Armstrong K; Karlan BY
Gynecol Oncol; 2007 Jan; 104(1):120-8. PubMed ID: 16956650
[TBL] [Abstract][Full Text] [Related]
15. Establishment and characterization of a new human cell-line (AMOC-2) derived from a serous adenocarcinoma of ovary.
Yabushita H; Ueno N; Sawaguchi K; Higuchi K; Noguchi M; Ishihara M
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Jul; 41(7):888-94. PubMed ID: 2794621
[TBL] [Abstract][Full Text] [Related]
16. Malignant behavior and resistance to cisplatin of human ovarian carcinoma xenografts established from the same patient at different stages of the disease.
Masazza G; Lucchini V; Tomasoni A; Peccatori F; Lampasona V; Giudici G; Mangioni C; Biondi A; Giavazzi R
Cancer Res; 1991 Dec; 51(23 Pt 1):6358-62. PubMed ID: 1933898
[TBL] [Abstract][Full Text] [Related]
17. Establishment of a human ovarian cancer cell line capable of forming ascites in nude mice and effects of tranexamic acid on cell proliferation and ascites formation.
Kikuchi Y; Kizawa I; Oomori K; Miyauchi M; Kita T; Sugita M; Tenjin Y; Kato K
Cancer Res; 1987 Jan; 47(2):592-6. PubMed ID: 3791243
[TBL] [Abstract][Full Text] [Related]
18. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK
Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591
[TBL] [Abstract][Full Text] [Related]
19. Ultrastructural and phenotypic characterization of CABA I, a new human ovarian cancer cell line.
Dolo V; Ginestra A; Violini S; Miotti S; Festuccia C; Miceli D; Migliavacca M; Rinaudo C; Romano FM; Brisdelli F; Canevari S; Pavan A; Vittorelli ML
Oncol Res; 1997; 9(3):129-38. PubMed ID: 9220498
[TBL] [Abstract][Full Text] [Related]
20. Isolation and preliminary characterization of an ovarian carcinoma cell line from a patient with familial ovarian cancer.
Buller RE; Niemann T; Connor JP; Squatrito RC; Skilling JS; Anderson B
Gynecol Oncol; 1995 Jan; 56(1):39-44. PubMed ID: 7821846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
